Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
a study on Limb-Girdle Muscular Dystrophy Muscular Dystrophies
Summary
- Eligibility
- for people ages 4-65 (full criteria)
- Location
- at UC Irvine
- Dates
- study startedcompletion around
Description
Summary
Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic development.
Official Title
GRASP-LGMD: Defining Clinical Endpoints in LGMD
Details
The genetic heterogeneity has been a barrier to broad natural history efforts, with prior investigations often limited to single gene mutations. Much attention is paid to the variability within individual mutations (e.g. distal presentations), as opposed to defining the best strategy for measuring change in overall LGMD disease burden. This presents a major dilemma for LGMD rare disease research: how to balance diverse genes leading to overlapping phenotypes, versus variants in the same gene leading to divergent phenotypes. What is clear, is as a group, LGMDs are chronic and progressive leading to significant lifetime morbidity and represent a large unmet clinical need.
Recent developments in the investigator's genetic understanding of LGMD and molecular approaches to therapy have led to proposed gene replacement therapies for at least three of the LGMD mutations. Several of these gene replacement therapies are currently in pre-clinical/phase 1 testing, leading to an urgent need for natural history data. In addition, non-specific therapies which target muscle mass or function are being tested in other muscular dystrophies and may prove beneficial for LGMD.
Keywords
Limb Girdle Muscular Dystrophy, Muscular Dystrophies, LGMD, CAPN3, ANO5, DYSF, DNAJB6, Sarcoglycan, SGCA, SGCB, SGCD, SGCG, Limb-Girdle Muscular Dystrophies, CAPN3 (LGMD2A), DYSF (LGMD2B), ANO5 (LGMD2L), DNAJB6 (LGMD1D), Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)
Eligibility
You can join if…
Open to people ages 4-65
- Arm 1:
- Age between 4-65 at enrollment
- Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
- A genetically or functionally confirmed mutation in ANO5, CAPN3, DYSF, DNAJB6 or SGCA-G.
- Willing and able to give informed consent and follow all study procedures and requirements
Inclusion Criteria - Arm 2:
- Age between 4-65 at enrollment
- Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
- a genetically confirmed mutation in SGCA-G
- Willing and able to give informed consent and follow all study procedures and requirements
You CAN'T join if...
- Arm 1:
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- History of a bleeding disorder, platelet count <50,000, current use of an anticoagulant.
- Positive pregnancy test at time any timepoint during the trial.
Exclusion Criteria - Arm 2:
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- History of a bleeding disorder, platelet count <50,000, current use of an anticoagulant
- Positive pregnancy test at time any timepoint during the trial.
Locations
- University of California Irvine
Irvine California 92697 United States - The University of Colorado Anschutz Medical Campus
Aurora Colorado 80045 United States
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Virginia Commonwealth University
- ID
- NCT03981289
- Study Type
- Observational
- Participants
- Expecting 80 study participants
- Last Updated